UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 14, 2014

 

Ultragenyx Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-36276

 

27-2546083

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

60 Leveroni Court, Novato, California

 

94949

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (415) 483-8800

Not Applicable

Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Item 8.01.  Other Events.

 

On August 14, 2014, the Company updated its corporate presentation, a copy of which is attached hereto as Exhibit 99.1 and incorporated by reference herein.

(d) Exhibits

 

Exhibit
No.

  

Description

99.1

  

Corporate Presentation, dated August 14, 2014

* * *

 

 

 

- 2 -

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 14, 2014

Ultragenyx Pharmaceutical Inc.

 

 

 

 

By:

 

/s/ Shalini Sharp

 

 

 

Shalini Sharp

 

 

 

Senior Vice President, Chief Financial Officer

 

 

 

- 3 -

 

Exhibit Index

 

Exhibit
No.

  

Description

99.1

  

Corporate Presentation, dated August 14, 2014

 

 

 

- 4 -